Biotech Industry · global
Basecamp raises $140 million to advance AI-designed in vivo cell therapies
Turning AI-designed DNA into therapies still requires overcoming challenges in delivery, gene integration, and safety validation. Basecamp’s new funding will support that development process; the funding news has also been corrected to clarify that Anthropic was not an investor in this round.
Modifying cells directly inside patients is the starting point Basecamp Research has chosen for AI drug design. The London-based company, which has a laboratory in Cambridge, Massachusetts, announced on September 23 that it had completed a $140 million Series C funding round to train the next generation of EDEN models and advance model-designed therapeutic candidates toward clinical development.
The round was led by S32, with participation from NVIDIA and Menlo Ventures’ Anthology Fund. However, the investor list in early reports has been corrected: BioSpace noted on September 25 that Basecamp’s original announcement had mistakenly listed Anthropic as an investor in the round. Anthropic’s technical collaboration with the company should not be conflated with an investment.
Basecamp’s initial focus, “in vivo cell therapy,” aims to reprogram patients’ cells inside the body. According to the company, the platform pairs long, complex DNA sequences designed by EDEN with large serine recombinases in an attempt to integrate those sequences into cellular genomes. If realized, the approach could enable cell therapies to perform more complex functions and simplify administration.
EDEN is supported by the company’s proprietary biological dataset, Trillion Gene Atlas. Basecamp says the data come from access and benefit-sharing partnerships spanning more than 30 countries and are used to train models to identify patterns in biological sequences and then generate potential therapeutic candidates. However, broad data coverage does not mean that the model’s outputs already have the efficacy and safety needed for use in humans.
Publicly available validation information remains limited. The company says it has achieved preclinical results across multiple therapeutic modalities and disease areas, but this funding announcement did not provide sufficient experimental data to assess their performance or specify a start date for the first human trial. Accordingly, “advancing toward clinical development” should be understood as an intended use of the funding and a development direction; it cannot yet be taken to mean that the therapies have entered human testing.
For therapies of this kind that write DNA into the genome, the questions that must be answered next are quite specific: whether the sequences can reach the intended cells, whether they integrate at appropriate sites, and whether the modified cells can function safely over the long term. These are also matters for which experimental evidence must be established individually as model designs progress toward clinical development and regulatory review.
Alongside the funding, Basecamp is also strengthening its partnership efforts. S32 general partner Andy Conrad has joined the board, while Richard Pearce, formerly of Biogen, has become chief business officer, responsible for expanding pharmaceutical partnerships. The funding gives the company more resources to connect computational design with therapeutic development; whether this can yield products suitable for clinical testing still depends on the therapeutic candidates and validation results disclosed in the future.